Type 2 Diabetes
Conditions
Brief summary
There is paucity of information about the combination therapy with dipeptidyl peptidase-4 inhibitor sitagliptin and insulin. This study aimed to retrospectively investigate the safety and efficacy of this therapeutic modality in Japanese patients with type 2 diabetes.
Interventions
None listed
Sponsors
The Japan Kidney Foundation
Kanagawa Physicians Association
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Inclusion criteria
* outpatients with type 2 diabetes * addition of sitagliptin to insulin therapy * aged 20 years or older * HbA1c of 6.9% or higher (NGSP) at the time of adding sitagliptin
Exclusion criteria
* history of hypersensitivity to sitagliptin * severe ketosis, diabetic coma, and/or precoma within 6 months before sitagliptin administration * sever infection and/or severe trauma, and/or patients who are scheduled to undergo / have recently underwent surgery * severe renal dysfunction (serum creatinine \[mg/dL\]: 2.5 or higher for men; 2.0 or higher for women) * ongoing treatment with glinide(s) * judgment as ineligible for the study by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood glucose level | Six months after starting sitagliptin-insulin combination therapy |
Countries
Japan
Outcome results
None listed